Tag:
IDX899
Latest Headlines
Latest Headlines
GSK licenses Idenix HIV drug for $450M
GSK has inked a $450 million deal for Idenix Pharmaceutical's experimental HIV/AIDS drug, IDX899. Idenix gets a $34 million up-front payment; half was cash and the rest came from a purchase of Idenix
